• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.

作者信息

Vellinga M M, Castelijns J A, Barkhof F, Uitdehaag B M J, Polman C H

机构信息

Department of Neurology, VU University Medical Center, de Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

出版信息

Neurology. 2008 Mar 25;70(13 Pt 2):1150-1. doi: 10.1212/01.wnl.0000265393.03231.e5. Epub 2007 Sep 13.

DOI:10.1212/01.wnl.0000265393.03231.e5
PMID:17872364
Abstract
摘要

相似文献

1
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.那他珠单抗治疗的多发性硬化症患者停药后T2病变活动的反弹增加。
Neurology. 2008 Mar 25;70(13 Pt 2):1150-1. doi: 10.1212/01.wnl.0000265393.03231.e5. Epub 2007 Sep 13.
2
Is natalizumab overshooting its rebound?那他珠单抗是否矫枉过正？
Neurology. 2008 Mar 25;70(13 Pt 2):1073-4. doi: 10.1212/01.wnl.0000306415.37679.5a.
3
Update. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Neurology. 2008 Sep 2;71(10):780. doi: 10.1212/01.wnl.0000334435.35213.87.
4
A giant MS plaque mimicking PML during natalizumab treatment.在那他珠单抗治疗期间形似 PML 的巨大 MS 斑块。
J Neurol Sci. 2010 Apr 15;291(1-2):110-3. doi: 10.1016/j.jns.2010.01.001. Epub 2010 Feb 7.
5
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.那他珠单抗治疗停止后多发性硬化症患者的免疫重建炎症综合征
Arch Neurol. 2011 Feb;68(2):186-91. doi: 10.1001/archneurol.2010.257. Epub 2010 Oct 11.
6
Diagnosis of melanoma under concomitant natalizumab therapy.在接受那他珠单抗联合治疗期间黑色素瘤的诊断
Mult Scler. 2011 Feb;17(2):255-6. doi: 10.1177/1352458510389629. Epub 2010 Dec 21.
7
Observations during an elective interruption of natalizumab treatment: a post-marketing study.择期中断那他珠单抗治疗期间的观察：一项上市后研究。
Mult Scler. 2011 Mar;17(3):372-5. doi: 10.1177/1352458510392098. Epub 2010 Dec 9.
8
Does natalizumab therapy worsen neuromyelitis optica?那他珠单抗疗法会加重视神经脊髓炎吗？
Neurology. 2012 Sep 4;79(10):1065-6. doi: 10.1212/WNL.0b013e31826845fe. Epub 2012 Aug 22.
9
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.抗那他珠单抗抗体的发生率及意义：来自AFFIRM和SENTINEL研究的结果
Neurology. 2007 Oct 2;69(14):1391-403. doi: 10.1212/01.wnl.0000277457.17420.b5. Epub 2007 Aug 29.
10
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.从那他珠单抗转换为芬戈莫德治疗后出现的肿胀性多发性硬化症。
Mult Scler. 2012 Nov;18(11):1650-2. doi: 10.1177/1352458512463768.

引用本文的文献

1
Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Multicenter, Prospective, Observational Study.从那他珠单抗转换为阿仑单抗的患者的疾病进程：一项意大利多中心前瞻性观察研究。
Neurol Ther. 2025 May 21. doi: 10.1007/s40120-025-00754-6.
2
A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.多发性硬化症疾病修正疗法手术部位感染的不均衡性分析
J Neurol. 2025 Feb 22;272(3):223. doi: 10.1007/s00415-025-12980-x.
3
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review.
使用单克隆抗体疗法治疗多发性硬化症：综述
Biologics. 2021 Jun 30;15:255-263. doi: 10.2147/BTT.S267273. eCollection 2021.
4
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.PML 风险是导致大型多发性硬化症患者停用那他珠单抗的主要因素：来自意大利多中心回顾性研究的结果。
J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28.
5
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.那他珠单抗在多发性硬化症患者中的药代动力学、药效动力学及血清神经丝蛋白情况
Front Neurol. 2021 Apr 14;12:650530. doi: 10.3389/fneur.2021.650530. eCollection 2021.
6
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice.在临床实践中从那他珠单抗转换为中等疗效与高疗效疾病修正治疗药物的效果。
Neurol Clin Pract. 2020 Dec;10(6):e53-e65. doi: 10.1212/CPJ.0000000000000809.
7
The Future of Progressive Multiple Sclerosis Therapies.进行性多发性硬化症治疗的未来
Fed Pract. 2020 Apr;37(Suppl 1):S43-S49.
8
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.芬戈莫德反弹：临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
9
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.多发性硬化症中那他珠单抗停药后疾病再激活：系统评价与荟萃分析
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809. doi: 10.1177/1756286419837809. eCollection 2019.
10
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.抗 TNF-R1 靶向治疗在多发性硬化症模型的人源化小鼠中改善疾病。
Sci Rep. 2018 Sep 11;8(1):13628. doi: 10.1038/s41598-018-31957-7.